The Cochlear Nucleus® Hybrid Implant System now covered by Anthem®; Hybrid Hearing now available to all with functional low frequency hearingCochlear CP920 Sound Processor with EAC200 Acoustic Component

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announces today that Anthem, the largest Blue Cross® and Blue Shield® (BCBS) franchise holder and second largest payer in the country, and six other independent BCBS plans have updated their cochlear implant coverage policies to include coverage for the Cochlear Nucleus Hybrid Implant System. This coverage is in addition to coverage by Aetna, TRICARE and Federal Employees Health Benefits (FEHB) Program already in place for the Hybrid System.

In 2014, Cochlear received U.S. Food and Drug Administration (FDA) approval for the only Hybrid Hearing* device available on the market. Since then, there has been limited access to the Hybrid Implant System for those with commercial insurance coverage, as can be the case with any new technology.

“Lack of awareness of treatment options and lack of access to insurance coverage impedes those with hearing loss to take action,” said Mickey Brown, Vice President, Health Economics, Cochlear North America. “Through Cochlear’s efforts to work with insurance companies throughout the United States, more than 90 million people now have access to all cochlear implant options available on the market.”

This exciting news also comes on the heels of the FDA approval of the Cochlear Nucleus Acoustic Component now being available for all customers with functional low frequency hearing regardless of the type of cochlear implant. Previous access to the Hybrid Implant System, which includes the acoustic component, was only available to those with the Hybrid L24 Implant**. Now, all cochlear implant customers can obtain the acoustic component if they have functional low frequency hearing.

Hybrid Hearing combines the benefits of hearing aids and cochlear implants in one device, allowing customers to get back the sounds they have been missing by amplifying the low frequency hearing a person does have while restoring access to the high frequency hearing they have lost. Hybrid Hearing is designed to help those with severe high frequency hearing loss and mild to moderate low frequency hearing loss.

Read the full press release here.

Click here to discover the benefits of Hybrid Hearing and if it could be a solution for you or a loved one.

* The Cochlear Nucleus Acoustic Component should only be used when behavioral audiometric thresholds can be obtained and the recipient can provide feedback regarding sound quality.

 ** The Hybrid L24 Implant is approved in the U.S. for adults ages 18 and older.

® ANTHEM is a registered trademark. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association.

Renee Oehlerking
Renee Oehlerking is the Public Relations Manager at Cochlear Americas where she is responsible for the region’s public relations and consumer marketing social media. Renee enjoys uncovering, telling and showcasing the inspiring stories of hearing implant recipients. As a recent transplant to Denver, Colorado, Renee enjoys exploring all that the state has to offer outdoors.